# Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

> **NCT06940895** · PHASE2 · COMPLETED · sponsor: **Narrows Institute for Biomedical Research** · enrollment: 5 (actual)

## Conditions studied

- Acanthosis Nigricans

## Interventions

- **DRUG:** Sirolimus 0.2%

## Key facts

- **NCT ID:** NCT06940895
- **Lead sponsor:** Narrows Institute for Biomedical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-01
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-07-18
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940895, "Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06940895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*